NCT00384839 - Vidaza to Restore Hormone Thx Prostate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Prostate Cancer

Interventions

DRUG

azacitidine for injectable suspension

Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.

Trial Locations (13)

New York Oncology Hematology, P.C., Albany

Virginia Oncology Associates, Norfolk

Raleigh Hematology Oncology Associates, Cary

Northwestern Carolina Oncology Hematology, Hickory

Cancer Centers of Florida, P.A., Ocoee

Minnesota Oncology Hematology, P.A., Minneapolis

Texas Oncology, P.A., Dallas

Tyler Cancer Center, Tyler

Texas Oncology, P.A., Fort Worth

Deke Slayton Cancer Center, Webster

Rocky Mountain Cancer Center-Midtown, Denver

Comprehensive Cancer Centers of Nevada, Las Vegas

Cancer Care Nrothwest-South, Spokane